On Nov 10, 2025, CGEN reported earnings of -0.07 USD per share (EPS) for Q3 25, beating the estimate of -0.08 USD, resulting in a 20.81% surprise. Revenue reached 1.89 million, compared to an expected 1.50 million, with a 26.17% difference. The market reacted with a +3.09% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 6 analysts forecast an EPS of 0.05 USD, with revenue projected to reach 1.38 million USD, implying an decrease of -171.43% EPS, and decrease of -26.82% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Nurix Therapeutics, Inc. Common stock
Report Date
Jan 28, 2026 For Q4 25
Estimate
-$0.88
Actual
-$0.82
Surprise
+7.66%
Regeneron Pharmaceuticals Inc
Report Date
Jan 30, 2026 For Q4 25
Estimate
$10.84
Actual
$11.44
Surprise
+5.52%
FAQ
What were Compugen Ltd's earnings and revenue for the latest quarter Q3 2025?
For Q3 2025, Compugen Ltd reported EPS of -$0.07, beating estimates by 20.81%, and revenue of $1.89M, 26.17% above expectations.
How did the market react to Compugen Ltd's Q3 2025 earnings?
The stock price moved up 3.09%, changed from $1.62 before the earnings release to $1.67 the day after.
When is Compugen Ltd expected to report next?
The next earning report is scheduled for Feb 19, 2026.
What are the forecasts for Compugen Ltd's next earnings report?
Based on 6
analysts, Compugen Ltd is expected to report EPS of $0.05 and revenue of $1.38M for Q4 2025.